ClinicalTrials.gg
CompletedNCT04612348Updated Jul 21, 2026Results posted

Gastric Ultrasound in Tube Fed Intubated Patients

An observational study in Critical Illness, sponsored by Joseph D. Tobias. Completed at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Joseph D. Tobias · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
45
Ages
Up to 18 Years
Sex
All
01

Study summary

This study will use point of care (POC) gastric ultrasound to confirm that nasojejunal tube (NJ) feeds result in minimal to no gastric content and therefore are low risk for aspiration and should be allowed at the very least to decrease the time that enteral feeds need to be held prior to a procedure or if they need to be held at all. This would allow critically ill children to receive the nutrition that they need to heal for longer periods of time. Using ultrasound would also potentially eliminate the need for exposure to x-rays to confirm tube placement. Most ICUs have a POC ultrasound machine so this would be any easy tool to access to improve patient care.

02

Conditions studied

  • Critical Illness

Browse trials for

03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's enrollment of 45 is below the median of 140 across 816 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critically ill children at Nationwide Children's Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all PICU patients intubated \< 7 days that are receiving NJ or NG feeds

Exclusion criteria

Exclusion Criteria:

  • patients that cannot be moved
  • patients with significant GI conditions affecting motility
  • patients intubated for more than seven days
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
45 participants (actual)
Patient registry
No

Groups and cohorts

  • NJ tube fed

    Critically ill children receiving nutrition via a nasojejunal feeding tube.

    Diagnostic Test: Ultrasound

  • NG tube fed

    Critically ill children receiving nutrition via a nasogastric feeding tube.

    Diagnostic Test: Ultrasound

Interventions

  • Diagnostic testUltrasound

    Point of care ultrasound to measure gastric contents.

06

What researchers measure

Primary outcomes

  1. Average Gastric Volume

    Median volume (mL/kg) of gastric contents measured by ultrasound.

    Time frame: Baseline - 5 days

Secondary outcomes

  1. Risk of Aspiration

    The potential risk of aspirating stomach contents if patient underwent intubation.

    Time frame: Baseline - 5 days

07

Results

Posted Jul 21, 2026

Participant flow

Participant flow — Overall Study
MilestonePost-pyloricGastric
Started1629
Completed1629
Not completed00

Outcome measures

PrimaryAverage Gastric Volume

Median volume (mL/kg) of gastric contents measured by ultrasound.

Time frame:
Baseline - 5 days
Reported as:
Median · milliters per killogram
Average Gastric Volume
milliters per killogramPost-pyloricGastric
Average Gastric Volume2.1 (1.1 to 4.5)0 (0 to 0.1)
SecondaryRisk of Aspiration

The potential risk of aspirating stomach contents if patient underwent intubation.

Time frame:
Baseline - 5 days
Reported as:
Count of participants · Participants
Risk of Aspiration
ParticipantsPost-pyloricGastric
Low risk163
High risk026

Adverse events

Collected over 5 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Post-pyloric0/16 (0%)0/16 (0%)0/16 (0%)
Gastric0/29 (0%)0/29 (0%)0/29 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Post-pyloricGastricTotal
<=18 years162945
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(months)Post-pyloricGastricTotal
Median12 (4 to 122)4 (2 to 16)6 (2 to 48)
Sex: Female, Male
Sex: Female, Male(Participants)Post-pyloricGastricTotal
Female6713
Male102232
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Post-pyloricGastricTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Post-pyloricGastricTotal
United States162945
Weight
Weight(kilograms)Post-pyloricGastricTotal
Median10.1 (5.0 to 37.3)7.6 (5.5 to 12.9)7.9 (5.0 to 15.2)
Height
Height(centimeters)Post-pyloricGastricTotal
Median76.1 (57.5 to 129.5)60 (53 to 77)62 (54 to 79)
PRISM
PRISM(Participants)Post-pyloricGastricTotal
Low risk82129
Moderate risk6511
Unknown235
08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Mar 2026, 60 months.

Results were first posted in Jul 2026, 4 months after primary completion.

Of 441 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 60 months is above that.

Counting every sponsor, half of 444 studies reached it within 23 months; a quarter within 12 and three quarters within 46.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Nov 3, 2020
StartActual
Feb 26, 2021
Primary completionActual
Mar 17, 2026
CompletionActual
Mar 17, 2026
Results first posted
Jul 21, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04612348
Lead sponsor
Joseph D. Tobias
Responsible party
Joseph D. Tobias (Chair, Dept. of Anesthesiology & Pain Medicine, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Nov 3, 2020
Start date
Feb 26, 2021
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026
Results posted
Jul 21, 2026
Last update
Jul 21, 2026

Study contacts

Joseph D Tobias, MD
principal investigator · Nationwide Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion